PE20030561A1 - Resolucion de sal quiral - Google Patents

Resolucion de sal quiral

Info

Publication number
PE20030561A1
PE20030561A1 PE2002000452A PE2002000452A PE20030561A1 PE 20030561 A1 PE20030561 A1 PE 20030561A1 PE 2002000452 A PE2002000452 A PE 2002000452A PE 2002000452 A PE2002000452 A PE 2002000452A PE 20030561 A1 PE20030561 A1 PE 20030561A1
Authority
PE
Peru
Prior art keywords
methyl
alkyl
amino
refers
pyrimidin
Prior art date
Application number
PE2002000452A
Other languages
English (en)
Spanish (es)
Inventor
Glenn Ernest Wilcox
Christian Koecher
Mark Edward Flanagan
Michael John Munchhof
Ton Vries
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030561(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030561A1 publication Critical patent/PE20030561A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2002000452A 2001-05-31 2002-05-29 Resolucion de sal quiral PE20030561A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29477501P 2001-05-31 2001-05-31
US34104801P 2001-12-06 2001-12-06

Publications (1)

Publication Number Publication Date
PE20030561A1 true PE20030561A1 (es) 2003-06-23

Family

ID=26968730

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000452A PE20030561A1 (es) 2001-05-31 2002-05-29 Resolucion de sal quiral

Country Status (52)

Country Link
US (2) US7301023B2 (OSRAM)
EP (3) EP1609781B1 (OSRAM)
JP (1) JP4381137B2 (OSRAM)
KR (5) KR100926875B1 (OSRAM)
CN (1) CN1729192A (OSRAM)
AP (1) AP1859A (OSRAM)
AR (2) AR037321A1 (OSRAM)
AT (1) ATE519741T1 (OSRAM)
AU (2) AU2002304401C1 (OSRAM)
BE (1) BE2017C032I2 (OSRAM)
BG (1) BG66489B1 (OSRAM)
BR (1) BR0209246A (OSRAM)
CA (1) CA2448281C (OSRAM)
CL (1) CL2008000762A1 (OSRAM)
CR (1) CR10177A (OSRAM)
CU (1) CU23337B7 (OSRAM)
CY (2) CY1113322T1 (OSRAM)
CZ (1) CZ304366B6 (OSRAM)
DK (1) DK1666481T3 (OSRAM)
EA (2) EA007251B1 (OSRAM)
EC (1) ECSP034865A (OSRAM)
EE (1) EE05332B1 (OSRAM)
ES (2) ES2369226T3 (OSRAM)
FR (1) FR17C1031I2 (OSRAM)
GE (1) GEP20063784B (OSRAM)
GT (2) GT200200100A (OSRAM)
HR (1) HRP20030943B1 (OSRAM)
HU (2) HU230876B1 (OSRAM)
IL (1) IL158588A0 (OSRAM)
IS (1) IS3023B (OSRAM)
LT (1) LTC1666481I2 (OSRAM)
LU (1) LUC00031I2 (OSRAM)
MA (1) MA27029A1 (OSRAM)
MX (1) MXPA03011062A (OSRAM)
MY (1) MY129649A (OSRAM)
NL (1) NL300887I2 (OSRAM)
NO (3) NO328578B1 (OSRAM)
NZ (2) NZ530380A (OSRAM)
OA (1) OA12612A (OSRAM)
PA (1) PA8546301A1 (OSRAM)
PE (1) PE20030561A1 (OSRAM)
PL (2) PL367945A1 (OSRAM)
PT (1) PT1666481E (OSRAM)
RS (1) RS52144B (OSRAM)
SI (1) SI1666481T1 (OSRAM)
SK (2) SK288192B6 (OSRAM)
TN (1) TNSN03128A1 (OSRAM)
TW (2) TWI316061B (OSRAM)
UA (1) UA80093C2 (OSRAM)
UY (1) UY27317A1 (OSRAM)
WO (1) WO2002096909A1 (OSRAM)
ZA (1) ZA200307982B (OSRAM)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
DZ3248A1 (fr) * 1999-12-10 2001-06-14 Pfizer Prod Inc Composés à base de pyrrolo[2,3-d]pyrimidine
ATE323704T1 (de) * 2000-06-26 2006-05-15 Pfizer Prod Inc Pyrrolo¬2,3-däpyrimidin verbindungen als immunosuppressive wirkstoffe
GT200200234A (es) 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE451104T1 (de) 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
ATE402700T1 (de) * 2002-08-27 2008-08-15 Merck Patent Gmbh Glycinamid-derivate als raf-kinase-hemmer
MXPA05005576A (es) 2002-11-26 2005-07-27 Pfizer Prod Inc Procedimiento de tratamiento del rechazo a un trasplante.
PT1656372E (pt) 2003-07-30 2013-06-27 Rigel Pharmaceuticals Inc Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
EP2363149A1 (en) 2004-05-03 2011-09-07 Novartis AG Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
CA2572314A1 (en) 2004-06-29 2006-01-12 Christopher N. Farthing Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity
TW200615268A (en) 2004-08-02 2006-05-16 Osi Pharm Inc Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
BRPI0517887A (pt) * 2004-11-24 2008-10-21 Novartis Ag combinações de inibidores de jaks
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
US8163767B2 (en) 2005-07-14 2012-04-24 Astellas Pharma Inc. Heterocyclic Janus Kinase 3 inhibitors
US8232394B2 (en) 2005-07-29 2012-07-31 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
EP1926735A1 (en) 2005-09-22 2008-06-04 Incyte Corporation Tetracyclic inhibitors of janus kinases
DK1966202T3 (da) 2005-12-13 2012-01-16 Incyte Corp Heteroarylsubstituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-d]pyrimidiner som Januskinaseinhibitorer
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
DK3070090T3 (en) 2007-06-13 2019-03-18 Incyte Holdings Corp USE OF SALTS OF THE JANUS-KINASE INHIBITOR (R) -3- (4- (7H-PYRROLO [2,3-D] PYRIMIDIN-4-YL) -1H-PYRAZOL-1-YL) -3- CYCLOPENTYL PROPANNITRIL
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
CN101743009A (zh) 2007-07-11 2010-06-16 辉瑞大药厂 治疗干眼病的药物组合物和方法
LT2265607T (lt) 2008-02-15 2017-03-27 Rigel Pharmaceuticals, Inc. Pirimidin-2-amino junginiai ir jų panaudojimas kaip jak kinazių slopiklių
CN102026999B (zh) 2008-03-11 2014-03-05 因塞特公司 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EA019973B1 (ru) 2008-04-16 2014-07-30 Портола Фармасьютиклз, Инк. ИНГИБИТОРЫ Syk ПРОТЕИНКИНАЗ
NZ588830A (en) 2008-04-22 2012-11-30 Portola Pharm Inc Inhibitors of protein kinases
CA2732628A1 (en) * 2008-08-01 2010-02-04 Biocryst Pharmaceuticals, Inc. Therapeutic agents
WO2010020905A1 (en) * 2008-08-20 2010-02-25 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
CA2752150A1 (en) * 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
ES2552805T3 (es) * 2009-04-20 2015-12-02 Auspex Pharmaceuticals, Llc Inhibidores piperidínicos de la cinasa Janus 3
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
AU2010249443B2 (en) 2009-05-22 2015-08-13 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011029804A1 (en) * 2009-09-10 2011-03-17 F. Hoffmann-La Roche Ag Inhibitors of jak
CA2777114C (en) 2009-10-09 2018-10-23 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
PH12012500583A1 (en) 2009-10-15 2012-10-22 Pfizer Pyrrolo[2,3-d] pyrimidine compounds
CA2782720A1 (en) 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
BR112012017269A2 (pt) * 2010-01-12 2016-05-03 Hoffmann La Roche compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos
MX2012009074A (es) 2010-02-05 2012-08-23 Pfizer Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
TWI694826B (zh) 2010-03-10 2020-06-01 美商英塞特公司 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物
MY161078A (en) 2010-05-21 2017-04-14 Incyte Holdings Corp Topical formulation for a jak inhibitor
WO2012061428A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2481397A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Pharmaceutical compositions comprising tasocitinib
EP2481411A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
JP5936628B2 (ja) 2011-02-18 2016-06-22 ノバルティス・ファルマ・アクチェンゲゼルシャフトＮｏｖａｒｔｉｓ Ｐｈａｒｍａ ＡＧ ｍＴＯＲ／ＪＡＫ阻害剤併用療法
EP2691395B1 (en) 2011-03-28 2017-08-30 ratiopharm GmbH Processes for preparing tofacitinib salts
US9050342B2 (en) 2011-03-29 2015-06-09 Pfizer Inc. Beneficial effects of combination therapy on cholesterol
CA2830463A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Pharmaceutical composition comprising tofacitinib and a penetration enhancer
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
AR086983A1 (es) 2011-06-20 2014-02-05 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
CA2844507A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag Jak pi3k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
SG11201402570QA (en) 2011-11-23 2014-06-27 Portola Pharm Inc Pyrazine kinase inhibitors
US10821111B2 (en) 2011-11-30 2020-11-03 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP3750544B1 (en) 2011-11-30 2025-03-05 Emory University Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
EP2791141B1 (en) 2011-12-15 2017-02-08 ratiopharm GmbH Tofacitinib mono-tartrate salt
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
WO2014016338A1 (en) 2012-07-25 2014-01-30 Lek Pharmaceuticals D.D. New synthetic route for the preparation of 3-amino-piperidine compounds
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
IL297429A (en) 2012-11-15 2022-12-01 Incyte Holdings Corp Sustained release dosage forms of roxolitinib
WO2014083150A1 (en) * 2012-11-30 2014-06-05 Lek Pharmaceuticals D.D. Preparation of 3-amino-piperidine compounds via nitro-tetrahydropyridine precursors
EP2935216B1 (en) 2012-12-17 2018-06-27 Sun Pharmaceutical Industries Limited Process for the preparation of tofacitinib and intermediates thereof
EP2938616A4 (en) 2012-12-28 2016-06-15 Glenmark Pharmaceuticals Ltd PROCESSING METHOD FOR THE PRODUCTION OF TOFACITINIB AND INTERMEDIATE PRODUCTS THEREOF
SI3290421T1 (sl) 2013-02-22 2019-03-29 Pfizer Inc. Kombinacija derivatov pirolo (2,3-D)pirimidina z enim ali več dodatnimi sredstvi za zaviranje z janusom povezane kinaze (JAK)
SI2964650T1 (sl) 2013-03-06 2019-05-31 Incyte Holdings Corporation Postopki in vmesne spojine za izdelavo inhibitorja JAK
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib
HUE049345T2 (hu) 2013-08-07 2020-09-28 Incyte Corp Nyújtott hatóanyag-leadású dózisformák JAK1 inhibitorhoz
CN104513248B (zh) * 2013-09-30 2019-05-24 重庆医药工业研究院有限责任公司 一种托法替尼中间体的纯化方法
HUE035264T2 (hu) 2013-12-05 2018-05-02 Pfizer Pirrolo[2,3-d]pirimidinil-, pirrolo[2,3-b]pirazinil- és pirrolo[2,3-d]-piridinil- akrilamidok
SI3539965T1 (sl) * 2013-12-09 2021-07-30 Unichem Laboratories Limited Izboljšan postopek za pripravo (3R,4R)-(1-benzil-4-metilpiperidin-3-il)-metilamina
CA2881262A1 (en) 2014-02-06 2015-08-06 Prabhudas Bodhuri Solid forms of tofacitinib salts
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
EP3180344B1 (en) 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
WO2016116025A1 (zh) * 2015-01-20 2016-07-28 南京明德新药研发股份有限公司 Jak抑制剂
BR112017001516B1 (pt) * 2015-02-17 2023-10-31 Amorepacific Corporation Método de ressolubilização quiral, estereoisômero, método para preparar um composto, composto, composição, e kit de ressolubilização quiral
CN104761556B (zh) * 2015-03-21 2017-06-23 河北国龙制药有限公司 托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法
EP3078665A1 (en) * 2015-04-10 2016-10-12 OLON S.p.A. Efficient method for the preparation of tofacitinib citrate
KR102006684B1 (ko) 2015-04-29 2019-08-02 우시 포춘 파마슈티컬 컴퍼니 리미티드 Jak 억제제
WO2016178110A1 (en) 2015-05-01 2016-11-10 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof
ES2822748T3 (es) 2015-05-29 2021-05-04 Wuxi Fortune Pharmaceutical Co Ltd Inhibidor de cinasa Janus
WO2017017542A1 (en) * 2015-07-27 2017-02-02 Unichem Laboratories Limited Tofacitinib orally disintegrating tablets
KR101771219B1 (ko) * 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
CN108472298B (zh) 2015-11-24 2021-04-20 深圳阿拉丁医疗科技有限公司 选择性激酶抑制剂
CN105348287A (zh) * 2015-11-30 2016-02-24 宁波立华制药有限公司 一种枸橼酸托法替布的新型合成工艺
KR102565407B1 (ko) * 2016-01-04 2023-08-10 (주)아모레퍼시픽 극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
US20190083609A1 (en) 2016-01-18 2019-03-21 Helmoltz Zentrum München - Deutsches Forschungszentrum Für Gesundheit And Umwelt (Gmbh) Tofacitinib as vaccination immune modulator
BR112018074621B1 (pt) 2016-06-30 2021-06-08 Daewoong Pharmaceutical Co., Ltd compostos derivados de pirazolopirimidina como inibidores de quinase, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
CN106831538B (zh) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 托法替尼中间体的制备方法
KR102398659B1 (ko) 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
CN107602569A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
KR102078805B1 (ko) 2017-11-30 2020-02-19 보령제약 주식회사 토파시티닙을 포함하는 약제학적 조성물
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102318929B1 (ko) 2017-12-28 2021-10-28 주식회사 대웅제약 카이네이즈 저해제로서의 옥시-플루오로피페리딘 유도체
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
RS63312B1 (sr) 2018-01-30 2022-07-29 Incyte Corp Procesi za pripremu (1-(3-fluoro-2-(trifluorometil)izonikotinil)piperidin-4-on)
CN111670036B (zh) * 2018-01-31 2024-08-09 安成生物科技股份有限公司 包含托法替尼的局部调配物
US12161748B2 (en) 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
MX2022012285A (es) 2018-03-30 2023-08-15 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
KR102131107B1 (ko) * 2019-01-15 2020-07-07 주식회사 다산제약 3-아미노-피페리딘 화합물의 신규한 제조 방법
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
GB2596942B (en) 2019-02-27 2023-05-10 Samson Clinical Pty Ltd Tofacitinib via oral mucosa for use in treatment of autoimmune hair loss or excessing hair shedding
WO2020183295A1 (en) 2019-03-13 2020-09-17 Intas Pharmaceuticals Ltd. Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
CN113993585B (zh) 2019-03-27 2024-10-01 英矽智能科技知识产权有限公司 双环jak抑制剂及其用途
US12227478B2 (en) 2019-04-05 2025-02-18 Yuhan Corporation Processes for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same
CN114727950A (zh) 2019-11-14 2022-07-08 辉瑞大药厂 1-(((2s,3s,4s)-3-乙基-4-氟-5-氧代吡咯烷-2-基)甲氧基)-7-甲氧基异喹啉-6-羧酰胺组合及口服剂型
EP4067354B1 (en) 2019-11-25 2025-10-22 Daewoong Pharmaceutical Co., Ltd. Novel triazolopyridine derivative and pharmaceutical composition comprising same
AU2021248720A1 (en) 2020-04-04 2022-11-03 Pfizer Inc. Methods of treating coronavirus disease 2019
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4308568A1 (en) * 2021-03-15 2024-01-24 Chiesi Farmaceutici S.p.A. Heterocyclic derivatives as janus kinase inhibitors
CN113549075B (zh) * 2021-06-23 2025-09-23 合肥华方医药科技有限公司 一种枸橼酸托法替布非对映异构体杂质的合成方法
EP4180042A1 (en) 2021-11-15 2023-05-17 Sanovel Ilac Sanayi Ve Ticaret A.S. A film coated tablet comprising micronized tofacitinib

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DK0682027T3 (da) 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
JPH07330732A (ja) * 1994-06-10 1995-12-19 Kyorin Pharmaceut Co Ltd 光学活性な３−アミノ−１−ベンジルピペリジン誘導体
US6136596A (en) * 1995-05-19 2000-10-24 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
CA2223081C (en) 1995-06-07 2001-03-06 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
WO1997002262A1 (en) 1995-07-05 1997-01-23 E.I. Du Pont De Nemours And Company Fungicidal pyrimidinones
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
ATE201873T1 (de) 1995-11-14 2001-06-15 Pharmacia & Upjohn Spa Aryl- und heteroaryl- purin- und pyridopyrimidin- derivate
EP0888349B1 (en) 1996-01-23 2002-05-22 Novartis AG Pyrrolopyrimidines and processes for their preparation
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU1794697A (en) 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
CZ8799A3 (cs) 1996-07-13 1999-06-16 Glaxo Group Limited Bicyklické heteroaromatické sloučeniny, způsob jejich výroby a farmaceutický prostředek
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
PT938486E (pt) 1996-08-23 2008-03-27 Novartis Ag Pirrolopirimidinas substituídas e processos para a sua preparação
WO1998023613A1 (en) 1996-11-27 1998-06-04 Pfizer Inc. Fused bicyclic pyrimidine derivatives
ATE391719T1 (de) 1997-02-05 2008-04-15 Warner Lambert Co Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation
JP2001520748A (ja) 1997-03-24 2001-10-30 ファルマシア・アンド・アップジョン・カンパニー Ｊａｋ２／サイトカイン受容体結合の阻害剤を同定する方法
CA2326383A1 (en) 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors
AU4317399A (en) 1998-05-28 1999-12-13 Parker Hughes Institute Quinazolines for treating brain tumor
ATE265458T1 (de) 1998-06-19 2004-05-15 Pfizer Prod Inc Pyrrolo(2,3-d)pyrimidin-verbindungen
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP2004504259A (ja) 1998-06-30 2004-02-12 パーカー　ヒューズ　インスティテュート Ｊａｋ−３インヒビターを用いたｃ−ｊｕｎ発現の阻害方法
JP2002523403A (ja) 1998-08-21 2002-07-30 パーカー ヒューズ インスティテュート キナゾリン誘導体
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
DZ3248A1 (fr) * 1999-12-10 2001-06-14 Pfizer Prod Inc Composés à base de pyrrolo[2,3-d]pyrimidine
ATE323704T1 (de) * 2000-06-26 2006-05-15 Pfizer Prod Inc Pyrrolo¬2,3-däpyrimidin verbindungen als immunosuppressive wirkstoffe
GT200200234A (es) * 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
CA2572314A1 (en) * 2004-06-29 2006-01-12 Christopher N. Farthing Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity

Also Published As

Publication number Publication date
AU2002304401C1 (en) 2009-03-05
AU2002304401B2 (en) 2008-04-17
SI1666481T1 (sl) 2012-11-30
CY2017028I2 (el) 2018-02-14
CY1113322T1 (el) 2016-06-22
UA80093C2 (uk) 2007-08-27
ES2393385T3 (es) 2012-12-20
KR20060014459A (ko) 2006-02-15
AU2008203170B2 (en) 2009-06-18
CZ304366B6 (cs) 2014-04-02
ECSP034865A (es) 2004-01-28
KR20080002931A (ko) 2008-01-04
EP1666481B1 (en) 2012-09-19
GT200200100AA (es) 2007-07-06
EP1609781B1 (en) 2011-08-10
TWI310384B (en) 2009-06-01
NO328578B1 (no) 2010-03-22
TNSN03128A1 (fr) 2005-12-23
LTC1666481I2 (lt) 2018-06-25
AR037321A1 (es) 2004-11-03
EP1392694A1 (en) 2004-03-03
HU230876B1 (hu) 2018-11-29
IL158588A0 (en) 2004-05-12
EP1609781A1 (en) 2005-12-28
PL228155B1 (pl) 2018-02-28
AP2002002550A0 (en) 2002-06-30
AR045680A2 (es) 2005-11-09
NZ530380A (en) 2005-08-26
MA27029A1 (fr) 2004-12-20
KR100868814B1 (ko) 2008-11-14
EP1666481B9 (en) 2013-05-01
SK288199B6 (sk) 2014-06-03
HRP20030943A2 (en) 2005-08-31
GEP20063784B (en) 2006-04-10
CZ20033260A3 (en) 2004-03-17
RS52144B (sr) 2012-08-31
FR17C1031I2 (fr) 2018-11-02
IS3023B (is) 2020-08-15
LUC00031I1 (OSRAM) 2017-08-10
KR20060133117A (ko) 2006-12-22
CU23337B7 (es) 2009-01-20
NO2017047I1 (no) 2017-09-08
SK288192B6 (sk) 2014-06-03
CN1729192A (zh) 2006-02-01
JP4381137B2 (ja) 2009-12-09
AU2008203170A1 (en) 2008-08-07
OA12612A (en) 2006-06-09
HUP0400152A2 (en) 2007-07-30
CY2017028I1 (el) 2018-02-14
EA012666B1 (ru) 2009-12-30
PL367945A1 (en) 2005-03-07
EP1666481A3 (en) 2006-11-29
IS6993A (is) 2003-10-13
CA2448281A1 (en) 2002-12-05
KR100926875B1 (ko) 2009-11-16
CL2008000762A1 (es) 2008-07-04
UY27317A1 (es) 2003-02-28
KR20080083028A (ko) 2008-09-12
US7301023B2 (en) 2007-11-27
YU92303A (sh) 2006-08-17
KR20040003037A (ko) 2004-01-07
AP1859A (en) 2008-07-02
TWI316061B (en) 2009-10-21
DK1666481T3 (da) 2012-10-15
NO20093135L (no) 2003-11-24
EA007251B1 (ru) 2006-08-25
TW200413370A (en) 2004-08-01
HUS1900008I1 (hu) 2020-02-28
KR100869409B1 (ko) 2008-11-21
US20030073719A1 (en) 2003-04-17
US20040229923A1 (en) 2004-11-18
HRP20030943B1 (hr) 2011-11-30
MY129649A (en) 2007-04-30
NO20035201L (no) 2003-11-24
BR0209246A (pt) 2004-06-15
LTPA2017025I1 (lt) 2017-09-11
EA200301193A1 (ru) 2004-04-29
SK14652003A3 (sk) 2004-05-04
NO20035201D0 (no) 2003-11-24
EP1666481A2 (en) 2006-06-07
ZA200307982B (en) 2004-10-14
PT1666481E (pt) 2012-12-03
BE2017C032I2 (OSRAM) 2021-07-19
WO2002096909A1 (en) 2002-12-05
EE200300594A (et) 2004-04-15
BG108389A (bg) 2005-01-31
US7432370B2 (en) 2008-10-07
JP2004534047A (ja) 2004-11-11
HUP0400152A3 (en) 2012-12-28
NL300887I2 (nl) 2017-08-31
ATE519741T1 (de) 2011-08-15
GT200200100A (es) 2003-02-11
LUC00031I2 (OSRAM) 2017-10-11
PL409305A1 (pl) 2014-12-22
FR17C1031I1 (fr) 2017-10-13
EE05332B1 (et) 2010-08-16
BG66489B1 (bg) 2015-05-29
PA8546301A1 (es) 2003-05-14
NZ540332A (en) 2007-05-31
MXPA03011062A (es) 2004-03-19
EA200600575A1 (ru) 2006-08-25
ES2369226T3 (es) 2011-11-28
CA2448281C (en) 2009-05-05
CR10177A (es) 2008-08-19

Similar Documents

Publication Publication Date Title
PE20030561A1 (es) Resolucion de sal quiral
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
ES2190396T3 (es) Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
CO5390079A1 (es) Compuestos heterociclicos novedosos que tienen actividades hipolipidemicas, hipocolesterolicas, proceso para su preparacion y composiciones farmaceuticas que los contienen y su uso en medicina
UY26968A1 (es) Agentes terapéuticos
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
AR027437A1 (es) Derivados de purina
BR0112242A (pt) Composições farmacêuticas de agentes estrogênicos
EA200400762A1 (ru) Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции
PA8495101A1 (es) Derivados de 13-metileritromicina
MEP32408A (en) Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
KR950704253A (ko) 5-HT₁-유사 작용제로서의 카바졸 유도체의 거울상이성질체(Enantiomers of Carbazole Derivatives as 5-HT₁-Like Agonists)
AR002990A1 (es) Una nueva combinacion de un inhibidor de reabsorcion de 5-ht y un antagonista 5-ht(1a), su uso para la preparacion de medicamentos, una formulacion farmaceutica que la comprende, un procedimiento para la preparacion de dicha combinacion y equipo que contiene dicha combinacion.
AR029347A1 (es) Compuesto de adenina, compuesto de isognanina y 2,6-ditioxantina como precursor del mismo, uso de dichos compuestos para preparar una composicion farmaceutica y dicha composicion farmaceutica
EA200400311A1 (ru) Кристаллы производных гидроксинорэфедрина
CA2406266A1 (en) A pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds
PA8534001A1 (es) Derivados de piperazina 1,4-disustituida utiles como bloqueadores alfa1,-adrenoceptores uro-selectivos
EA200700144A1 (ru) Производные пиридопиримидина, их получение, их применение в терапии
ES2153457T3 (es) Amino-alquil-benzoxazolinonas y benzotiazolinonas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
PT937043E (pt) Novos derivados tetra-hidropiridinicos substituidos processo para a sua preparacao e as composicoes farmaceuticas que os contem
BR0013694A (pt) Composto, processo para a preparação de um composto, composição farmacêutica, e, uso de um composto
ES8304122A1 (es) "procedimiento para la preparacion de derivados triptaminicos sustituidos de tieniloxipropanolaminas, racemicos y opticamente activos".
JPS6466116A (en) Antiemetic containing specific substituted phenylalkylamino and amino acid derivatives and compound selected from other serotonin drying drugs
RU94032285A (ru) Цефалоспориновые соединения, способ их получения, фармацевтическая композиция
SE9900190D0 (sv) New compounds

Legal Events

Date Code Title Description
FC Refusal